第二组固有淋巴细胞（ILC2）在过敏性气道炎症和感染期间，协调第二型免疫反应至关重要。据报道，ILC2在肿瘤中发挥调节作用，但这个结论存在争议。在本研究中，我们证明IL-33激活的ILC2能够通过直接抗原交叉呈递来促进CD8+ T细胞功能。IL-33激活后，ILC2显示出提升的抗原处理能力和CD8+ T细胞活化能力。激活的ILC2能够在体内和体外吞噬外源性抗原，促进特异性抗原CD8+ T细胞功能，增强抗肿瘤免疫反应。注射OVA负载的ILC2在OVA表达的肿瘤模型中表现出强大的抗肿瘤效果。这些发现表明，注射肿瘤抗原负载的ILC2可能作为一种潜在的癌症治疗策略。© 2023年作者。 发表许可：Taylor & Francis Group, LLC.

Group 2 innate lymphoid cells (ILC2s) are essential for orchestrating type 2 immune responses during allergic airway inflammation and infection. ILC2s have been reported to play a regulatory role in tumors; however, this conclusion is controversial. In this study, we showed that IL-33-activated ILC2s could boost CD8+ T-cell function through direct antigen cross-presentation. After activation by IL-33, ILC2s showed an enhanced potential to process antigens and prime CD8+ T cell activation. Activated ILC2s could phagocytose exogenous antigens in vivo and in vitro, promoting antigen-specific CD8+ T cell function to enhance antitumor immune responses. Administration of OVA-loaded ILC2s induces robust antitumor effects on the OVA-expressing tumor model. These findings suggested that the administration of tumor antigen-loaded ILC2s might serve as a potential strategy for cancer treatment.© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.